Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Lexicon Pharmaceuticals in a research note issued on Friday, March 7th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.09) per share for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals' Q2 2025 earnings at ($0.09) EPS and Q3 2025 earnings at ($0.10) EPS.
Other research analysts have also recently issued research reports about the company. Leerink Partnrs cut Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. Leerink Partners reaffirmed a "market perform" rating and issued a $1.00 price objective (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Piper Sandler dropped their target price on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. StockNews.com started coverage on shares of Lexicon Pharmaceuticals in a report on Wednesday. They set a "sell" rating on the stock. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $3.67.
Check Out Our Latest Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Trading Down 6.0 %
NASDAQ:LXRX traded down $0.02 during trading hours on Monday, reaching $0.36. 4,135,852 shares of the company were exchanged, compared to its average volume of 3,980,885. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.64. The stock has a 50 day simple moving average of $0.70 and a 200 day simple moving average of $1.11. The firm has a market cap of $88.15 million, a price-to-earnings ratio of -0.48 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. The firm had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%.
Institutional Trading of Lexicon Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter worth about $115,000. Charles Schwab Investment Management Inc. lifted its holdings in Lexicon Pharmaceuticals by 4.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,417,295 shares of the biopharmaceutical company's stock worth $2,225,000 after acquiring an additional 58,147 shares during the last quarter. FMR LLC lifted its holdings in Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company's stock worth $78,291,000 after acquiring an additional 11,179,919 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company's stock valued at $50,000 after acquiring an additional 13,246 shares during the period. Finally, BBR Partners LLC grew its holdings in shares of Lexicon Pharmaceuticals by 74.1% during the third quarter. BBR Partners LLC now owns 470,000 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 200,000 shares during the last quarter. Institutional investors own 74.70% of the company's stock.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Read More
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
